A randomized, double-blind, placebo controlled, two-way cross-over study to explore the effects of 7 days of dosing with SYN115 20 mg p.o. bid or 60 mg p.o. bid on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Tozadenant (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Synosia Therapeutics
- 13 Jun 2010 Perfusion MRI results presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
- 14 Apr 2010 Perfusion MRI results presented at the 62nd Annual Meeting of the American Academy of Neurology.
- 14 Apr 2010 Results presented at 62nd Annual Meeting of the American Academy of Neurology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History